HSP90 Inhibition Suppresses PGE2 Production via Modulating COX-2 and 15-PGDH Expression in HT-29 Colorectal Cancer Cells
- 432 Downloads
The existence of multiple-interactive roles between several signaling pathways in tumorigenesis shows the significance of pharmacological factors like heat shock protein 90 (HSP90) inhibitors which control several signaling pathways simultaneously. HSP90 as a molecular chaperone supports the active conformational structure and function of several oncogenic signal proteins, termed “client” proteins, some of them act as a link between cancer and inflammation. Prostaglandin E2 (PGE2) is one of the major mediators of inflammation in colorectal cancer development and progress. However, the relationship between chaperone activity of HSP90 and PGE2 levels remains unclear. We evaluated the inhibitory effects of 17-demethoxy-17-allylamino geldanamycin (1 7-AAG), an HSP90 inhibitor, on PGE2 levels in HT-29 colorectal cancer cells. For the first time, we showed inhibitory effects of 17-AAG, on PGE2 levels in HT-29 colorectal cancer cells. 17-AAG inhibited PMA-induced cyclooxygenase-2 (COX-2) mRNA expression and protein level. We showed 15-hydroxyprostaglandin dehydrogenase (15-PGDH) expression induced by 17-AAG treatment at both mRNA and protein levels. In conclusion, we found that inhibitory effects of 17-AAG on PGE2 levels in HT-29 colorectal cancer cells were mediated through modulating COX-2 and 15-PGDH expression.
KEY WORDSHSP90 PGE2 COX-2 15-PGDH colorectal cancer
The authors thank the Deputy of Research Affairs of Kerman University of Medical Sciences for funding this project.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 4.Khanna, M., F. Wang, I. Jo, W.E. Knabe, S.M. Wilson, L. Li, K. Bum-Erdene, J. Li, G. W Sledge, R. Khanna, and S.O. Meroueh. 2011. Targeting multiple conformations leads to small molecule inhibitors of the uPAR.uPA protein-protein interaction that block cancer cell invasion. ACS Chemical Biology 6: 1232–43.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Sevin M, Girodon F, Garrido C, and de Thonel A. HSP90 and HSP70: Implication in inflammation processes and therapeutic approaches for myeloproliferative neoplasms. 2015. Mediators Inflamm: 970242. doi: 10.1155/2015/970242.
- 18.Xian, Y.F., Y.C. Li, S.P. Ip, Z.X. Lin, X.P. Lai, and Z.R. Su. 2011. Anti-inflammatory effect of patchouli alcohol isolated from Pogostemonis Herba in LPS-stimulated RAW264.7 macrophages. ExpTher Med 2: 545–50.Google Scholar
- 19.Choi, Y.E., C. Battelli, J. Watson, J. Liu, J. Curtis, A.N. Morse, U.A. Matulonis, D. Chowdhury, and P.A. Konstantinopoulos. 2014. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget 5: 2678–87.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Zarghi, A., and S. Arfaei. 2011. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran Journal of Pharmacy Research 10: 655–83.Google Scholar
- 26.Kang, S., A. Min, S.A. Im, S.H. Song, S.G. Kim, H.A. Kim, H.J. Kim, D.Y. Oh, H.S. Jong, T.Y. Kim, and Y.J. Bang. 2015. TGF-beta suppresses COX-2 expression by tristetraprolin-mediated RNA destabilization in A549 human lung cancer cells. Cancer Research and Treatment 47: 101–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Reti, A., G. Barna, E. Pap, V. Adleff, V. LK, A. Jeney, J. Kralovánszky, and B. Budai. 2009. Enhancement of 5-fluorouracil efficacy on high COX-2 expressing HCA-7 cells by low dose indomethacin and NS-398 but not on low COX-2 expressing HT-29 cells. Pathology Oncology Research 15: 335–44.CrossRefPubMedGoogle Scholar
- 29.Kaidi, A., D. Qualtrough, A.C. Williams, and C. Paraskeva. 2006. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Research 66: 6683–91.CrossRefPubMedGoogle Scholar
- 32.Chi, X., B.M. Freeman, M. Tong, Y. Zhao, and H.H. Tai. 2009. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Archives of Biochemistry and Biophysics 487: 139–45.CrossRefPubMedGoogle Scholar
- 37.Chandramouli, A., M.E. Mercado-Pimentel, A. Hutchinson, A. Gibadulinova, E.R. Olson, S. Dickinson, R. Shañas, J. Davenport, J. Owens, A.K. Bhattacharyya, J.W. Regan, et al. 2010. The induction of S100p expression by the prostaglandin E(2) (PGE(2))/EP4 receptor signaling pathway in colon cancer cells. Cancer Biology & Therapy 10: 1056–66.CrossRefGoogle Scholar
- 40.Solomon, S.D., J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk, and M. Bertagnolli. 2005. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine 352: 1071–80.CrossRefPubMedGoogle Scholar